|Videos|February 10, 2017
FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year
Advertisement
Gina Columbus reports on an FDA approval and 2 priority reviews in bladder cancer, highlights from the 2017 European Cancer Congress, a European approval in lung cancer, and ASCO announces its Cancer Advance of the Year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5































